Analyst Rating Update on Repros Therapeutics (RPRX)

Repros Therapeutics (RPRX) has an average broker rating of 3, which is interpreted as a Hold, as rated by 2 equity analysts. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Company shares have received an average consensus rating of Hold for the current week


Repros Therapeutics (NASDAQ:RPRX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.07 and $1.96 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.34. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.19, notching a gain of 5.80% for the day. The total traded volume was 784,455 . The stock had closed at $2.07 on the previous day.

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Companys product candidates include Androxal and Proellex. The Companys primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men. The Companys Proellex product candidate for female reproductive health is a chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *